Breitmeyer James B
- SEC CIK
- 0001244823
No open-market purchases or sales filed in the past year.
Current role at each company
- VXRT Vaxart, Inc.Directoras of Jul 17, 2026
- ONCT Oncternal Therapeutics, Inc.Chief Executive Officeras of Feb 15, 2024
- OTIC Otonomy, Inc.Directoras of Jun 23, 2022
- ZGNX Zogenix, Inc.Directoras of Mar 9, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Breitmeyer James B as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ONCT Oncternal Therapeutics, Inc.
Chief Executive Officer2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2023 (view filing)6:00 AM ET | Apr 13-14 | 4 days | Breitmeyer James BChief Executive Officer | PPurchase | +150.0K | $0.2929 | +$43.9K | +322.3%196.5K after | 3 lots |
| Jan 31, 2022 (view filing) | Jan 27 | 4 days | Breitmeyer James BChief Executive Officer | PPurchase | +25.0K | $1.68 | +$42.0K | +116.0%46.5K after |